TEL AVIV—Teva Pharmaceutical Industries expects to finalize an opioid settlement in the United States by year-end and start paying in 2023, its chief executive said on Sunday, while confirming he was unlikely to renew his contract next year.
After years of negotiations, Israel-based Teva in July proposed a $4.35 billion nationwide settlement—mostly cash and partly medicines that will amount to $300 million to $400 million over 13 years—to resolve its opioid lawsuits.
